Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Arienti

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Human Gene Therapy|October 20, 1996
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cellsF Arienti, J Sulé-Suso, F Belli, et al.
Folia Biologica|January 1, 1996
Cytokine-based gene therapy of human tumors. An overviewG Parmiani, F Arienti, J Sulé-Suso, et al.
Human Gene Therapy|September 1, 1994
Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytesF Arienti, J Sulé-Suso, C Melani, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocolsM A Player, K C Barracchini, T B Simonis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapyL Rivoltini, D J Loftus, K Barracchini, et al.
Critical Reviews in Immunology|January 7, 1998
Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivityL Rivoltini, D J Loftus, P Squarcina, et al.
Journal of the National Cancer Institute|October 4, 1995
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibodyS Canevari, G Stoter, F Arienti, et al.
European Journal of Nuclear Medicine|May 1, 1997
Comparison of three different methods for radiolabelling human activated T lymphocytesC Botti, D R Negri, E Seregni, et al.
Human Gene Therapy|December 28, 1999
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cellsF Arienti, F Belli, F Napolitano, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1997
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerabilityF Belli, F Arienti, J Sulé-Suso, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Human Gene Therapy|October 20, 1996
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cellsF Arienti, J Sulé-Suso, F Belli, et al.
Folia Biologica|January 1, 1996
Cytokine-based gene therapy of human tumors. An overviewG Parmiani, F Arienti, J Sulé-Suso, et al.
Human Gene Therapy|September 1, 1994
Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytesF Arienti, J Sulé-Suso, C Melani, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocolsM A Player, K C Barracchini, T B Simonis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapyL Rivoltini, D J Loftus, K Barracchini, et al.
Critical Reviews in Immunology|January 7, 1998
Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivityL Rivoltini, D J Loftus, P Squarcina, et al.
Journal of the National Cancer Institute|October 4, 1995
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibodyS Canevari, G Stoter, F Arienti, et al.
European Journal of Nuclear Medicine|May 1, 1997
Comparison of three different methods for radiolabelling human activated T lymphocytesC Botti, D R Negri, E Seregni, et al.
Human Gene Therapy|December 28, 1999
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cellsF Arienti, F Belli, F Napolitano, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1997
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerabilityF Belli, F Arienti, J Sulé-Suso, et al.
Pageof 4